Drug Patents owned by Vivus
1. List of Qsymia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895057 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(5 years from now) | |
| US9011906 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(5 years from now) | |
| US9011905 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(5 years from now) | |
| US8895058 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(5 years from now) | |
| US8580298 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
May, 2029
(6 years from now) | |
| US8580299 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 24, 2025 |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient
Market Authorisation Date: 17 July, 2012
Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of QSYMIA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic